by Rod Raynovich | May 10, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and...
by Rod Raynovich | Apr 19, 2010 | BIOgraph
At yesterday’s AACR (American Association of Cancer Research) Meeting in Washington DC researchers presented results from the Battle Trial which is a hypothesis- driven prospective study that identifies biomarkers(BM’s) to predict tumor response and thus...
by Rod Raynovich | Mar 30, 2010 | BIOgraph
US Judge invalidates cancer gene patents Intellectual Property (IP) is the raw material for the creation of biotech companies. Without an invention covered by a robust patent portfolio, venture funding can be very difficult. Since the beginning of the “genomic...
by Rod Raynovich | Feb 9, 2010 | BIOgraph
Genomic Health (GHDX) 2/4/10 Molecular Diagnostics and Genomics Public Company- Market Cap $482M Stock Price $16.5-17.5 Summary Genomic Health is a life science Company focused on the development and commercialization of genomic-based clinical laboratory services for...
by Rod Raynovich | Dec 23, 2009 | BIOgraph
CompuGen, an early stage drug and diagnostic discovery Company announced today a “Discovery on Demand” therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon CompuGen in silico discovery platforms. The predicted...
